Denmark-based company GN Hearing maintains its guidance for 2021, and thus, still envisions organic growth in the 25 percent range and an earnings before interest, taxation and amortization (EBITA) margin at more than 16 percent, which the company communicates in an announcement to the stock exchange on Wednesday morning in a financial update containing preliminary figures for the firm's Q1.
"We still expect that the EBITA margin in a more normalized market in the second half-year of 2021 will improve to reach our goal in the medium-long term at more than 20 percent," GN writes.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.